China will overtake SA as our biggest market, says Aspen CEO Stephen Saad
Aspen Pharmacare sees China eventually overtaking SA as its biggest market, as the company completes its transition to a global therapeutics business from an Africa-focused maker of generic drugs. The business sells medicines in more than 150 countries and is looking for partners as it expands in China, the Middle East and the US. The infant-milk formula market is just one area that represents a good opportunity in Asia’s most populous nation as the market consolidates, CEO Stephen Saad said on Thursday. "Four years ago, Asia was less than 10% of total commercial pharma revenue, while China is now number three by sales and Asia is bigger than Australia," he said in an interview. "China has every opportunity to get to number one," he added, declining to comment on how long it would take. Revenue from therapeutic brands, which include anaesthetic and blood-clotting medicines, rose to 45% of first-half sales after the company said in September it would buy more rights to AstraZeneca’s ...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.